For chronically depressed patients who have not responded to prior treatments, mindfulness-based cognitive therapy (MBCT) produces clinical benefits that persist for at least six months after the program ends. Depressive symptoms, quality of life, rumination, mindfulness skills, and self-compassion all remained stable during follow-up, and remission rates actually increased further. Patients who entered treatment with higher levels of rumination showed greater reductions in depressive symptoms and better quality of life at six months, after accounting for initial symptom severity. Other factors—duration of the current depressive episode, degree of treatment resistance, childhood trauma, and baseline mindfulness or self-compassion—did not predict outcomes.
Mindfulness-based cognitive therapy (MBCT) is effective for patients with remitted or currently active depression, but its effectiveness for those with chronic, treatment-resistant depression has not yet been established.
A randomized controlled trial will compare Mindfulness-Based Cognitive Therapy (MBCT) plus treatment-as-usual (TAU) against TAU alone for patients with chronic, treatment-resistant depression who have already received antidepressant medication and either cognitive behavioral therapy or interpersonal therapy. The primary outcome is depressive symptoms; secondary outcomes include remission rates, quality of life, rumination, mindfulness skills, and self-compassion. Assessments occur at baseline and after the intervention or TAU period, with follow-up at three and six months post-MBCT for completers. The trial aims to provide information on MBCT's effectiveness in this population.